AI-based prediction of actionable genomic alterations from H&E-stained slides

Precision oncology based on the identification of actionable genomic alterations (AGAs) has been transformative in the care of solid tumors, yet optimal treatment selection is often hindered by tissue exhaustion and slow turnaround times. Artificial intelligence (AI) addresses these barriers by predicting AGAs directly from routine hematoxylin and eosin (H&E)-stained slides. Recent landmark studies, including the prospective EAGLE and ANNAR trials, have demonstrated that deep learning models can identify alterations such as EGFR in non-small cell lung cancer and FGFR in urothelial cancer across diverse global cohorts. By providing near-instant, non-destructive results, AI-based prediction can triage patients for molecular testing or clinical trials at the time of initial diagnosis. This perspective evaluates the maturing evidence base and outlines a pragmatic pathway for integrating these tools into clinical practice. Ultimately, these models offer the opportunity to extract critical molecular information from slides generated in every laboratory worldwide and to significantly improve timely access to the rapidly evolving therapeutic landscape of solid tumors.

Authors

Institutions

Publication Details

Journal
npj Precision Oncology
Published
2026-11-13
DOI
https://doi.org/10.1038/s41698-026-01772-9
Primary Topic
AI in cancer detection
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

AI-based prediction of actionable genomic alterations from H&E-stained slides

Woochan Hwang, Kashif Alam Firozvi, Vivek Subbiah, Fernando López‐Ríos et al.
4 links
npj Precision Oncology
AI in cancer detection
article

AI-based prediction of actionable genomic alterations from H&E-stained slides

Woochan Hwang, Kashif Alam Firozvi, Vivek Subbiah, Fernando López‐Ríos, Siraj Mahamed Ali
article en

Abstract

Precision oncology based on the identification of actionable genomic alterations (AGAs) has been transformative in the care of solid tumors, yet optimal treatment selection is often hindered by tissue exhaustion and slow turnaround times. Artificial intelligence (AI) addresses these barriers by predicting AGAs directly from routine hematoxylin and eosin (H&E)-stained slides. Recent landmark studies, including the prospective EAGLE and ANNAR trials, have demonstrated that deep learning models can identify alterations such as EGFR in non-small cell lung cancer and FGFR in urothelial cancer across diverse global cohorts. By providing near-instant, non-destructive results, AI-based prediction can triage patients for molecular testing or clinical trials at the time of initial diagnosis. This perspective evaluates the maturing evidence base and outlines a pragmatic pathway for integrating these tools into clinical practice. Ultimately, these models offer the opportunity to extract critical molecular information from slides generated in every laboratory worldwide and to significantly improve timely access to the rapidly evolving therapeutic landscape of solid tumors.

npj Precision OncologyVol. 10(1)
Universidad Complutense de Madrid (ES), Mount Auburn Hospital (US), Research Institute Hospital 12 de Octubre (ES), Maryland Oncology Hematology (US), Hospital Universitario 12 De Octubre (ES), Stanford Medicine (US), Centro de Investigación Biomédica en Red de Cáncer (ES), Lunit (South Korea) (KR), Stanford University (US)
Good health and well-being
AI in cancer detection
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon